Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Jul. 31, 2022	Jul. 31, 2020	Feb. 29, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				$ 26,909	$ 14,267	$ 31,992
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 14,561			14,661	506	21,208
Upfront and Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized from previously deferred balances				14,561	397	20,205
Alaunos Therapeutics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				100	100	200
Oragenics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				0	0	3,053
Revenue recognized from previously deferred balances		$ 2,823
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				3,768	0	0
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				10,793	0	0
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				0	388	17,810
Revenue recognized from previously deferred balances			$ 10,000
Other revenues | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues				$ 0	$ 18	$ 145